4.8 Article

Calixarene-Embedded Nanoparticles for Interference-Free Gene-Drug Combination Cancer Therapy

Journal

SMALL
Volume 17, Issue 8, Pages -

Publisher

WILEY-V C H VERLAG GMBH
DOI: 10.1002/smll.202006223

Keywords

calixarene-embedded nanoparticle; combination therapy; CRISPRi system; drug antagonism; host-guest complexation

Funding

  1. National Key Research and Development Programs of China [2018YFA0209700]
  2. National Natural Science Foundation of China (NSFC) [51673100, 21620102005]
  3. Fundamental Research Funds for the Central Universities (Nankai University) [ZB19100123, ZB16008705]
  4. Tianjin Natural Science Foundation [18JCQNJC03600]

Ask authors/readers for more resources

CENP, a novel nanoparticle, co-delivers molecular drugs and therapeutic genes for interference-free gene-drug combination cancer therapy, showing significantly enhanced anti-tumor effects. With the potential to be a universal platform adaptable for various drug and gene combinations, CENP holds promise for the development of effective cancer treatments.
Combination therapy based on molecular drugs and therapeutic genes provides an effective strategy for malignant tumor treatment. However, effective gene and drug combinations for cancer treatment are limited by the widespread antagonism between therapeutic genes and molecular drugs. Herein, a calixarene-embedded nanoparticle (CENP) is developed to co-deliver molecular drugs and therapeutic genes without compromising their biological functions, thereby achieving interference-free gene-drug combination cancer therapy. CENP is composed of a cationic polyplex core and an acid-responsive polymer shell, allowing CENP loading and delivering therapeutic genes with improved circulation stability and enhanced tumor accumulation. Moreover, the introduction of carboxylated azocalix[4]arene, which is a hypoxia-responsive calixarene derivatives, in the polyplex core endows CENP with the capability to load molecular drugs through the host-guest complexation as well as inhibit the interference between the drugs and genes by encapsulating the drugs into its cavity. By loading doxorubicin and a plasmid DNA-based CRISPR interference system that targets miR-21, CENP exhibits the significantly enhanced anti-tumor effects in mice. Considering the wide variety of calixarene derivatives, CENP can be adapted to deliver almost any combination of drugs and genes, providing the potential as a universal platform for the development of interference-free gene-drug combination cancer therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available